Achieve Life Sciences Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Achieve Life Sciences de 57.1% y 74% respectivamente, mientras que el BPA crecerá en un 58.8% al año.

Información clave

57.1%

Tasa de crecimiento de los beneficios

58.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.5%
Tasa de crecimiento de los ingresos	74.0%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Good
Última actualización	11 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Jun 29

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Apr 04

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Mar 22

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

Jun 14

We're Keeping An Eye On Achieve Life Sciences' (NASDAQ:ACHV) Cash Burn Rate

Mar 01

Achieve Life Sciences prices stock offering at $7; shares down 2%

Dec 03

Achieve Life Sciences launches equity offering

Nov 30

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:ACHV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	32	-29	-46	-45	6
12/31/2025	N/A	-47	-50	-48	8
12/31/2024	N/A	-38	-23	-31	8
9/30/2024	N/A	-33	-25	-25	N/A
6/30/2024	N/A	-28	-20	-20	N/A
3/31/2024	N/A	-27	-21	-21	N/A
12/31/2023	N/A	-30	-24	-24	N/A
9/30/2023	N/A	-36	-31	-31	N/A
6/30/2023	N/A	-42	-37	-37	N/A
3/31/2023	N/A	-44	-39	-39	N/A
12/31/2022	N/A	-42	-38	-38	N/A
9/30/2022	N/A	-38	-32	-32	N/A
6/30/2022	N/A	-32	-29	-29	N/A
3/31/2022	N/A	-33	-30	-30	N/A
12/31/2021	N/A	-33	-29	-29	N/A
9/30/2021	N/A	-31	-27	-27	N/A
6/30/2021	N/A	-28	-22	-22	N/A
3/31/2021	N/A	-19	-15	-15	N/A
12/31/2020	N/A	-15	-13	-13	N/A
9/30/2020	N/A	-13	-14	-14	N/A
6/30/2020	N/A	-13	-13	-13	N/A
3/31/2020	N/A	-14	-15	-15	N/A
12/31/2019	N/A	-16	-15	-15	N/A
9/30/2019	N/A	-17	-15	-15	N/A
6/30/2019	N/A	-16	-15	-15	N/A
3/31/2019	N/A	-16	-13	-13	N/A
12/31/2018	N/A	-13	-11	-11	N/A
9/30/2018	N/A	-13	-11	-11	N/A
6/30/2018	N/A	-16	N/A	-13	N/A
3/31/2018	N/A	-13	N/A	-11	N/A
12/31/2017	N/A	-11	N/A	-9	N/A
9/30/2017	N/A	-7	N/A	-6	N/A
3/31/2017	N/A	-1	N/A	0	N/A
12/31/2016	N/A	-1	N/A	0	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ACHV sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que ACHV sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que ACHV sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que ACHV no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que ACHV no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ACHV se prevé que sea elevada dentro de 3 años.

Achieve Life Sciences Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 17% to US$19.71

Price target decreased by 12% to US$24.71

Price target decreased by 8.1% to US$27.57

Forecast to breakeven in 2025

Price target increased by 10% to US$27.43

Price target increased by 14% to US$28.33

Recent updates

New major risk - Financial position

Achieve Life Sciences, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Achieve Life Sciences, Inc Promotes Jaime Xinos to Chief Commercial Officer

Achieve Life Sciences, Inc. Announces Appointment of Mark L. Rubinstein as Head of Medical Affairs

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces CEO Changes

New minor risk - Profitability

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

Achieve Life Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement

Achieve Life Sciences, Inc. Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Achieve Life Sciences, Inc., Annual General Meeting, Jun 05, 2024

Achieve Life Sciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 17% to US$19.71

Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting

Achieve Life Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Financial position

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $60.000002 million.

Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

New minor risk - Profitability

Price target decreased by 12% to US$24.71

New minor risk - Share price stability

Price target decreased by 8.1% to US$27.57

Achieve Life Sciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is Achieve Life Sciences (NASDAQ:ACHV) Using Debt In A Risky Way?

Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

New minor risk - Market cap size

New major risk - Financial position

Achieve Life Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

Achieve Life Sciences, Inc. Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

Forecast to breakeven in 2025

Price target increased by 10% to US$27.43

Executive Chairman exercised options and sold US$69k worth of stock

High number of new directors

Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?

Price target increased by 14% to US$28.33

Achieve Life Sciences, Inc. Announces Last Subject Dosed in Phase 2 Orca-V1 Trial of Cytisinicline for E-Cigarette Cessation

Dialectic Capital Engages in Discussions with Achieve Life Sciences

Achieve Life Sciences, Inc. Announces That the Final Subject of the Company’s Phase 3 ORCA-3 Trial Has Completed Treatment in the Study

Achieve Life Sciences, Inc. Receives Written Notification from the Listing Qualifications Staff of the Nasdaq Stock Market

Consensus revenue estimates fall by 33%

Price target decreased to US$28.13

Achieve Life Sciences, Inc. announced that it expects to receive CAD 18.930777 million in funding

Achieve Life Sciences, Inc. Announces Early Completion of Target Enrollment in Cytisinicline E-Cigarette Cessation Trial

Achieve Life Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

Consensus revenue estimates fall by 33%

Achieve Life Sciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine E-Cigarette Cessation

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Achieve Life Sciences Inc. Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine E-Cigarette Users

Price target increased to US$34.13

Achieve Life Sciences Announces Positive Topline Results from Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Price target decreased to US$31.50

Achieve Life Sciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Achieve Life Sciences, Inc., Annual General Meeting, May 31, 2022

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Consensus revenue estimates fall by 73%

Achieve Life Sciences, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Achieve Life Sciences Announces Initiation of the Phase 3 Orca-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

Achieve Life Sciences, Inc. Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$39.50